Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly Partners with WHO Foundation on Global Obesity Health Systems – $1.68 Million Commitment Through 2029

Fineline Cube Mar 11, 2026
Company Deals Drug

AstraZeneca Initiates CLARITY-Gastric 02 Phase III – Sonesitatug Vedotin Combo Triggers $45 Million Milestone from KYM Biosciences

Fineline Cube Mar 11, 2026
Company Deals

GSK Licenses Linerixibat to Alfasigma for $300 Million Upfront – IBAT Inhibitor Targets PBC Pruritus with $690 Million Total Deal Value

Fineline Cube Mar 10, 2026
Company Deals Drug

Novo Nordisk Settles with Hims & Hers – Ozempic Wegovy Distribution Deal Ends Patent Litigation, Eliminates Compounded GLP-1 Advertising

Fineline Cube Mar 10, 2026
Company Deals

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Fineline Cube Mar 9, 2026
Policy / Regulatory

FDA Streamlines Biosimilar Development – New Guidance Cuts PK Study Costs by 50%, Accelerates Path to Market

Fineline Cube Mar 10, 2026
Company Drug

J&J’s AKEEGA Wins EU Approval for mHSPC – PARP/Abiraterone Combo Expands to Earlier-Line Prostate Cancer

Fineline Cube Mar 11, 2026
Company Drug

Abbisko’s ABSK061 Wins FDA Rare Pediatric Disease Designation – FGFR2/3 Inhibitor Targets Achondroplasia

Fineline Cube Mar 11, 2026
Company Deals

Gene Solutions Partners with Shenzhen USK Bio to Advance Precision Oncology in Southern China

Fineline Cube Jun 16, 2025

Vietnam-headquartered Gene Solutions announced a Memorandum of Understanding (MOU) with China’s Shenzhen USK Bioscience Co.,...

Company Deals

MRI and Astellas Alliance to Boost Japanese Drug Discovery Startups

Fineline Cube Jun 16, 2025

Japan-based Mitsubishi Research Institute, Inc. (MRI) and Astellas Pharma Inc. (TYO: 4503) announced the signing...

Company Drug

MSD Wins NMPA Approval for Keytruda-Lenvima Combo in Hepatocellular Carcinoma

Fineline Cube Jun 16, 2025

US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) announced that China’s National Medical Products Administration...

Company Deals

Xuanzhu Biopharma Files for Hong Kong IPO to Advance Innovative Drug Pipeline

Fineline Cube Jun 16, 2025

Xuanzhu Biopharmaceutical Co., Ltd., a subsidiary of China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460),...

Company Drug

Roche Imposes New Dosing Restrictions on Elevidys for Non-Ambulatory DMD Patients

Fineline Cube Jun 16, 2025

Swiss pharmaceutical giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced immediate new dosing restrictions for...

Company Drug

Innovent Biologics Initiates Phase III Trial for Mazdutide in OSA and Obesity

Fineline Cube Jun 16, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced the dosing of the first participant in China...

Company Drug

Abbisko Therapeutics Launches Clinical Study of FGFR4 Inhibitor in Advanced Hepatocellular Carcinoma

Fineline Cube Jun 16, 2025

Shanghai-based Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced the dosing of the first patient in...

Company Deals

Dessight Biomedical Secures RMB 100M Series A Funding for Surgical Robot Development

Fineline Cube Jun 16, 2025

Hangzhou-based Dessight Biomedical, a provider of ultra-microsurgery precision solutions, has completed a Series A funding...

Company Drug

AstraZeneca Launches Truqap in China for PIK3CA/AKT1/PTEN-Altered Breast Cancer

Fineline Cube Jun 16, 2025

UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) announced the official commercial launch of Truqap (capivasertib) in...

Company Deals

CR Sanjiu Partners with HELP Therapeutics to Advance iPSC-based Heart Failure Therapy

Fineline Cube Jun 16, 2025

China-based CR Sanjiu (SHE: 000999), a state-owned pharmaceutical company, announced a partnership with Nanjing-based HELP...

Company Deals Hospital

Raffles Medical Partners with CQMU First Hospital to Enhance Healthcare Services

Fineline Cube Jun 16, 2025

Singapore-based Raffles Medical Group, a leading integrated healthcare provider with a broad presence in Asia,...

Company Deals

AstraZeneca and CSPC Pharma Collaborate on Novel Oral Drug Discovery

Fineline Cube Jun 16, 2025

UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) and China’s CSPC Pharmaceutical Group Ltd (HKG: 1093)...

Company Deals

CF PharmTech Files for Hong Kong IPO to Expand Respiratory Disease Treatments

Fineline Cube Jun 16, 2025

China-based CF PharmTech, Inc., a specialist in inhalable drugs for respiratory diseases, has filed for...

Company Deals

Cloudbreak Pharma Files for Hong Kong IPO Amid Ophthalmic Drug Development

Fineline Cube Jun 16, 2025

Cloudbreak Pharma Inc. has submitted another initial public offering (IPO) filing to the Hong Kong...

Company Deals

Nona Biosciences Licenses HCAb Technology to Visterra for Biologic Development

Fineline Cube Jun 13, 2025

Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), announced a licensing agreement with...

Company Deals

BioNTech in Deal to Acquire CureVac for $1.25B to Boost Cancer mRNA Therapies

Fineline Cube Jun 13, 2025

Germany-based BioNTech SE (NASDAQ: BNTX) announced plans to acquire all outstanding shares of fellow German...

Company Drug

AbbVie’s Mavyret Gains FDA Approval for Acute HCV in Children and Adults

Fineline Cube Jun 13, 2025

US-based AbbVie (NYSE: ABBV) announced that the US Food and Drug Administration (FDA) has approved...

Company Drug

Zhaoke Ophthalmology’s TAB014 Receives BLA Review for wAMD Treatment

Fineline Cube Jun 13, 2025

China-based Zhaoke Ophthalmology Ltd (HKG: 6622) announced that its Biologic License Application (BLA) for TAB014,...

Company Deals

GSK Licenses Shigella Vaccine to Bharat Biotech for Low- and Middle-Income Countries

Fineline Cube Jun 13, 2025

UK-based GSK plc (NYSE: GSK) announced a licensing agreement with Bharat Biotech International Limited, an...

Company Drug

Merck Launches Phase III Trial for Quadrivalent Dengue Vaccine V181

Fineline Cube Jun 13, 2025

US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) announced the launch of the Phase III...

Posts pagination

1 … 111 112 113 … 633

Recent updates

  • Eli Lilly Partners with WHO Foundation on Global Obesity Health Systems – $1.68 Million Commitment Through 2029
  • J&J’s AKEEGA Wins EU Approval for mHSPC – PARP/Abiraterone Combo Expands to Earlier-Line Prostate Cancer
  • Abbisko’s ABSK061 Wins FDA Rare Pediatric Disease Designation – FGFR2/3 Inhibitor Targets Achondroplasia
  • Zelgen’s Zesuning Launches Nationwide – First China-Approved Recombinant TSH for Thyroid Cancer Follow-Up
  • Fosun Pharma’s Tenapanor (Vteglea) Issues First China Prescription – NHE3 Inhibitor Targets Hyperphosphatemia in Dialysis Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Eli Lilly Partners with WHO Foundation on Global Obesity Health Systems – $1.68 Million Commitment Through 2029

Company Drug

J&J’s AKEEGA Wins EU Approval for mHSPC – PARP/Abiraterone Combo Expands to Earlier-Line Prostate Cancer

Company Drug

Abbisko’s ABSK061 Wins FDA Rare Pediatric Disease Designation – FGFR2/3 Inhibitor Targets Achondroplasia

Company Drug

Zelgen’s Zesuning Launches Nationwide – First China-Approved Recombinant TSH for Thyroid Cancer Follow-Up

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.